What can we learn from patient-reported outcomes of insulin pen devices?

Journal of Diabetes Science and Technology

Volumn 5, Issue 6, 2011, Pages 1563-1571

  Anderson, Barbara J ^a   Redondo, Maria J ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Adherence; Diabetes; Insulin therapy; Pen; Syringe

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

DIABETES MELLITUS; DRUG SELF ADMINISTRATION; HUMAN; PATIENT PREFERENCE; REVIEW; STATISTICS;

DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PATIENT PREFERENCE; SELF ADMINISTRATION;

EID: 84862653963     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681100500633     Document Type: Review

References (81)

1. Silverstein J, Klingensmith G, Copeland K, Plotnick L, Kaufman F, Laffel L, Deeb L, Grey M, Anderson B, Holzmeister LA, Clark N; American Diabetes Association. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care. 2005;28(1):186-212. (Pubitemid 40095803)
2. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31(1):81-6.
3. National Committee for Quality Assurance. The state of health care quality. http://www.ncqa.org/Portals/0/State-of-Health-Care/2010/SOHC-2010- Full2.pdf. Accessed March 1, 2010.
4. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-59.
5. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
6. Bonafede MM, Kalsekar A, Pawaskar M, Ruiz KM, Torres AM, Kelly KR, Curkendall SM. Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysis. BMC Endocr Disord. 2011;11:3.
7. Perfetti R. Reusable and disposable insulin pens for the treatment of diabetes: understanding the global differences in user preference and an evaluation of inpatient insulin pen use. Diabetes Technol Ther. 2010;12 Suppl 1:S79-85.
8. Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther. 2010;12 Suppl 1:S101-8.
9. Luijf YM, DeVries JH. Dosing accuracy of insulin pens versus conventional syringes and vials. Diabetes Technol Ther. 2010;12 Suppl 1:S73-7.
10. Pfützner A, Asakura T, Sommavilla B, Lee W. Insulin delivery with FlexPen: dose accuracy, patient preference and adherence. Expert Opin Drug Deliv. 2008;5(8):915-25.
11. Dang DK, Lee J. Analysis of symposium articles on insulin pen devices and alternative insulin delivery methods. J Diabetes Sci Technol. 2010;4(3):558-61.
12. Goldstein HH. Pen devices to improve patient adherence with insulin therapy in type 2 diabetes. Postgrad Med. 2008;120(3):172-9.
13. Pearson TL. Practical aspects of insulin pen devices. J Diabetes Sci Technol. 2010;4(3):522-31.
14. Lee LJ, Li Q, Reynolds MW, Pawaskar MD, Corrigan SM. Comparison of utilization, cost, adherence, and hypoglycemia in patients with type 2 diabetes initiating rapid-acting insulin analog with prefilled pen versus vial/syringe. J Med Econ. 2011;14(1):75-86.
15. Molife C, Lee LJ, Shi L, Sawhney M, Lenox SM. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol Ther. 2009;11(8):529-38.
16. Lee IT, Liu HC, Liau YJ, Lee WJ, Huang CN, Sheu WH. Improvement in health-related quality of life, independent of fasting glucose concentration, via insulin pen device in diabetic patients. J Eval Clin Pract. 2009;15(4):699-703.
17. Albano S; Orbiter Study Group. Assessment of quality of treatment in insulin-treated patients with diabetes using a pre-filled insulin pen. Acta Biomed. 2004;75(1):34-9.
18. Korytkowski M, Bell D, Jacobsen C, Suwannasari R; FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25(11):2836-48. (Pubitemid 37510593)
19. Bradley C. The diabetes treatment satisfaction questionnaire: DTSQ. In: Bradley C, ed. Handbook of psychology and diabetes: a guide to psychological measurement in diabetes research and practice. Chur: Harwood Academic Publishers; 1994, 111-32.
20. Anderson RT, Skovlund SE, Marrero D, Levine DW, Meadows K, Brod M, Balkrishnan R. Development and validation of the insulin treatment satisfaction questionnaire. Clin Ther. 2004;26(4):565-78. (Pubitemid 38586458)
21. Stockl K, Ory C, Vanderplas A, Nicklasson L, Lyness W, Cobden D, Chang E. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe. Curr Med Res Opin. 2007;23(1):133-46. (Pubitemid 46191679)
22. Brod M, Skovlund SE, Wittrup-Jensen KU. Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience. Qual Life Res. 2006;15(3):481-91.
23. Mukherjee AK, Reddy VS, Shah S, Jhingan AK, Ramakrishnan P, Prusty V, Singh NS. Quality of life as a key indicator of patient satisfaction and treatment compliance in people with type 2 diabetes mellitus in the IMPROVE study: a multicentre, open label, non-randomised, observational trial. J Indian Med Assoc.2009;107(7):464-70.
24. Rex J, Jensen KH, Lawton SA. A review of 20 years' experience with the NovoPen family of insulin injection devices. Clin Drug Investig. 2006;26(7):367-401. (Pubitemid 43927053)
25. Arslanoǧlu I, Saka N, Bundak R, Günöz H, Darendeliler F. A comparison of the use of premixed insulins in pen-injectors with conventional patient-mixed insulin treatment in children and adolescents with IDDM. Is there a decreased risk of night hypoglycemia? J Pediatr Endocrinol Metab.2000;13(3):313-8. (Pubitemid 30163757)
26. Barnett AH, Bowen Jones D, Burden AC, Janes JM, Sinclair A, Small M, Tindall H. Multicentre study to assess quality of life and glycaemic control of Type 2 diabetic patients treated with insulin compared with oral hypoglycaemic agents. Pract Diabetes Int.1996;13(6):179-83. (Pubitemid 27022882)
27. Berger AS, Saurbrey N, Kühl C, Villumsen J. Clinical experience with a new device that will simplify insulin injections. Diabetes Care.1985;8(1):73-6. (Pubitemid 15172390)
28. Bohannon NJ, Ohannesian JP, Burdan AL, Holcombe JH, Zagar A. Patient and physician satisfaction with the Humulin/Humalog Pen, a new 3.0-mL prefilled pen device for insulin delivery. Clin Ther.2000;22(9):1049-67.
29. Buysschaert M, Janne P, Mpoy M, Reynaert C, Pirson F, Cassiers L, Lambert AE. Metabolic and psychological evolution of insulin dependent diabetic patients during a 6 months insulin-pen treatment. Diabete Metab. 1988;14(2):75-9.
30. Chantelau E, Schiffers T, Schütze J, Hansen B. Effect of patient-selected intensive insulin therapy on quality of life. Patient Educ Couns. 1997;30(2):167-73. (Pubitemid 27094790)
31. Chen HS, Hwu CM, Kwok CF, Yang HJ, Shih KC, Lin BJ, Ho LT. Clinical response and patient acceptance of a prefilled, disposable insulin pen injector for insulin-treated diabetes. Zhonghua Yi Xue Za Zhi (Taipei). 1999;62(7):455-60. (Pubitemid 29340734)
32. Coscelli C, Lostia S, Lunetta M, Nosari I, Coronel GA. Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Res Clin Pract. 1995;28(3):173-7.
33. Dahl-Jorgensen K, Hanssen KF, Mosand R, Sandvik L. The "insulin pen": Comparison with multiple injection treatment with syringe. Pract Diabetes Int. 1986;3(2):90-1. (Pubitemid 16020021)
34. Davis EM, Christensen CM, Nystrom KK, Foral PA, Destache C. Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization. Am J Health Syst Pharm. 2008;65(14):1347-57.
35. Dunbar JM, Madden PM, Gleeson DT, Fiad TM, McKenna TJ. Premixed insulin preparations in pen syringes maintain glycemic control and are preferred by patients. Diabetes Care. 1994;17(8):874-8. (Pubitemid 24235510)
36. Engström LH. Insulin pen for administration of isophane insulin. Pract Diabetes Int. 1990:7(4):162-4. (Pubitemid 20238910)
37. Fox C, McKinnon C, Wall A, Lawton SA. Ability to handle, and patient preference for, insulin delivery devices in visually impaired patients with type 2 diabetes. Pract Diabetes Int. 2002;19(4):104-7.
38. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998;20(3):486-96. (Pubitemid 28343501)
39. Hanas R, Ludvigsson J. Experience of pain from insulin injections and needle-phobia in young patients with IDDM. Pract Diabetes Int. 1997;14(4):95-9. (Pubitemid 27359267)
40. Hörnquist JO, Wikby A, Andersson PO, Dufva AM. Insulin-pen treatment, quality of life and metabolic control: retrospective intragroup evaluations. Diabetes Res Clin Pract.1990;10(3):221-30.
41. Houtzagers CM, Berntzen PA, van der Stap H, van Maarschalkerweerd WW, Lanting P, Boen-Tan I, Heine RJ, van der Veen EA. Efficacy and acceptance of two intensified conventional insulin therapy regimens: a long-term cross-over comparison. Diabet Med. 1989;6(5):416-21. (Pubitemid 19161365)
42. Houtzagers CM, Visser AP, Berntzen PA, van der Stap H, van Maarschalkerweerd WW, Heine RJ, van der Veen EA. Multiple daily insulin injections improve self-confidence. Diabet Med.1989;6(6):512-9. (Pubitemid 19184617)
43. Hung CT, Wang FF. Pen injector for insulin-requiring diabetic patients. J Formos Med Assoc.1992;91(10):1026-9. (Pubitemid 23034598)
44. Ignaut DA, Schwartz SL, Sarwat S, Murphy HL. Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen. Diabetes Educ.2009;35(5):789-98.
45. Jørgensen JO, Flyvbjerg A, Jørgensen JT, Sørensen HH, Johansen BR, Christiansen JS. NPH insulin administration by means of a pen injector. Diabet Med. 1988;5(6):574-6.
46. Kadiri A, Chraibi A, Marouan F, Ababou MR, el Guermai N, Wadjinny A, Kerfati A, Douiri M, Bensouda JD, Belkhadir J, Arvanitis Y. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Diabetes Res Clin Pract. 1998;41(1):15-23. (Pubitemid 28394280)
47. Kølendorf K, Beck-Nielsen H, Oxenbøll B. Clinical experience with NovoPen II and insulin Protaphane HM Penfill. Postgrad Med J.1988;64 Suppl 3:14-6.
48. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26 Suppl 3:S18-24. (Pubitemid 35034478)
49. Martin JM, Llewelyn JA, Ristic S, Bates PC. Acceptability and safety of a new 3.0 ml re-usable insulin pen (HumaPen) in clinical use. Diabetes Nutr Metab.1999;12(5):306-9. (Pubitemid 30009009)
50. Murray DP, Keenan P, Gayer E, Salmon P, Tomkin GH, Drury MI, O'Sullivan DJ. A randomized trial of the efficacy and acceptability of a pen injector. Diabet Med.1988;5(8):750-4.
51. O'Hagan M, Greene SA. Pre-mixed insulin delivered by disposable pen in the management of children with diabetes. Diabet Med.1993;10(10):972-5. (Pubitemid 23359007)
52. Rowe BR, Pizzey M, Barnett AH. A clinical evaluation of the B-D Pen. Pract Diabetes Int. 1992;9(4):138-9.
53. Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care.2008;31(3):430-2.
54. Saurbrey N, Berger A, Kühl C. The NovoPen - a practical tool for simplifying multiple injection insulin therapy. Acta Paediatr Scand Suppl.1985;320:64-5. (Pubitemid 16125129)
55. Schönle EJ. [Intensive insulin therapy in adolescents with type 1 diabetes mellitus: initial experiences with a semiautomatic insulin injection device (the insulin pen)]. Schweiz Med Wochenschr.1987;117(45):1756-60.
56. Schuster MW, Chauhan SP, McLaughlin BN, Perry KG Jr, Morrison JC. Comparison of insulin regimens and administration modalities in pregnancy complicated by diabetes. J Miss State Med Assoc.1998;39(2):51-5.
57. Small M, MacRury S, Boal A, Paterson KR, MacCuish AC. Comparison of conventional twice daily subcutaneous insulin administration and a multiple injection regimen (using the NovoPen) in insulin-dependent diabetes mellitus. Diabetes Res.1988;8(2):85-9.
58. Spijker AJ, Hoekstra JB, Erkelens DW. The insulin pen: a new device for multiple insulin injections. Transplant Proc.1986;18(6):1689-90. (Pubitemid 17012315)
59. Stocks A, Perry SR, Brydon P; Australian HumaPen Collaborative Research Group. HumaPen Ergo(R): a new 3.0ml reusable insulin pen: evaluation of patient acceptability. Clin Drug Invest. 2001;21(5):319-24. (Pubitemid 32488754)
60. Sucic M, Galic E, Cabrijan T, Ivandic A, Petrusic A, Wyatt J, Mincheva N, Milicevic Z, Malone J. Patient acceptance and reliability of new Humulin/Humalog 3.0 ml prefilled insulin pen in ten Croatian diabetes centres. Med Sci Monit. 2002;8(3):PI21-6. (Pubitemid 34263058)
61. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther. 2004;26(9):1498-505. (Pubitemid 39572159)
62. Tallroth G, Karlson B, Nilsson A, Agardh CD. The influence of different insulin regimens on quality of life and metabolic control in insulin-dependent diabetics. Diabetes Res Clin Pract. 1989;6(1):37-43. (Pubitemid 19021833)
63. Tubiana-Rufi N, Levy-Marchal C, Mugnier E, Czernichow P. Long term feasibility of multiple daily injections with insulin pens in children and adolescents with diabetes. Eur J Pediatr. 1989;149(2):80-3. (Pubitemid 20000986)
64. Wilk T, Mora PF, Chaney S, Shaw K. Use of an insulin pen by homeless patients with diabetes mellitus. J Am Acad Nurse Pract. 2002;14(8):372-9.
65. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 2006;32 (1 Suppl):9S-18S. (Pubitemid 43206838)
66. McConnell EM, Harper R, Campbell M, Nelson JK. Achieving optimal diabetic control in adolescence: the continuing enigma. Diabetes Metab Res Rev. 2001;17(1):67-74. (Pubitemid 32203873)
67. Khan H, Lasker SS, Chowdhury TA. Prevalence and reasons for insulin refusal in Bangladeshi patients with poorly controlled Type 2 diabetes in East London. Diabet Med. 2008;25(9):1108-11.
68. Iwanaga M, Kamoi K. Patient perceptions of injection pain and anxiety: a comparison of NovoFine 32-gauge tip 6mm and Micro Fine Plus 31-gauge 5mm needles. Diabetes Technol Ther. 2009;11(2):81-6.
69. McKay M, Compion G, Lytzen L. A comparison of insulin injection needles on patients' perceptions of pain, handling, and acceptability: a randomized, open-label, crossover study in subjects with diabetes. Diabetes Technol Ther. 2009;11(3):195-201.
70. Hirsch LJ, Gibney MA, Albanese J, Qu S, Kassler-Taub K, Klaff LJ, Bailey TS. Comparative glycemic control, safety and patient ratings for a new 4 mm x 32G insulin pen needle in adults with diabetes. Curr Med Res Opin. 2010;26(6):1531-41.
71. Siegmund T, Blankenfeld H, Schumm-Draeger PM. Comparison of usability and patient preference for insulin pen needles produced with different production techniques: "thin-wall" needles compared to "regular-wall" needles: an open-label study. Diabetes Technol Ther.2009;11(8):523-8.
72. Taddio A, Chambers CT, Halperin SA, Ipp M, Lockett D, Rieder MJ, Shah V. Inadequate pain management during routine childhood immunizations: the nerve of it. Clin Ther. 2009;31 Suppl 2:S152-67.
73. Diglas J, Feinböck C, Irsigler K, Winkler F, Egger T, Weitgasser R, Pieber T, Lytzen L. Reduced pain perception with Pen Mate, an automatic needle insertion device for use with an insulin pen. Pract Diabetes Int. 1999;16(2):39-41. (Pubitemid 29229578)
74. Sommavilla B, Jørgensen C, Jensen KH. Safety, simplicity and convenience of a modified prefilled insulin pen. Expert Opin Pharmacother. 2008;9(13):2223-32.
75. Donsmark M, Herold L, Kristensen CM. A comparison of injection force and dosage scale size between NovoPen 3 and NovoPen 4. Diabetes Technol Ther. 2009;11(9):581-5.
76. Venekamp WJ, Kerr L, Dowsett SA, Johnson PA, Wimberley D, McKenzie C, Malone J, Milicevic Z. Functionality and acceptability of a new electronic insulin injection pen with a memory feature. Curr Med Res Opin. 2006;22(2):315-25. (Pubitemid 44296755)
77. Olsen BS, Lilleøre SK, Korsholm CN, Kracht T. Novopen Echo® for the delivery of insulin: a comparison of usability, functionality and preference among pediatric subjects, their parents, and health care professionals. J Diabetes Sci Technol. 2010;4(6):1468-75.
78. Olsen BS, Lilleøre SK. NovoPen Echo™ for the delivery of insulin in paediatric patients: a comparison of usability, functionality and preference among patients, their parents and healthcare professionals. Pediatr Diabetes. 2009;10 Suppl 11:30-109.
79. Clark PE, Okenfuss CR, Campbell M. Half-unit dose accuracy with HumaPen Luxura HD: an insulin pen for patients who need precise dosing. J Diabetes Sci Technol. 2010;4(2):353-6.
80. Hyllested-Winge J, Jensen KH, Rex J. A review of 25 years' experience with the NovoPen family of insulin pens in the management of diabetes mellitus. Clin Drug Investig. 2010;30(10):643-74.
81. Magnotti MA, Rayfield EJ. An analysis of the HumaPen Luxura HD pen: what is the role of 0.5-unit insulin dosing? J Diabetes Sci Technol. 2010;4(2):357-8.